Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:
TESARO Inc (NASDAQ:TSRO)’s shares picked up 6.71%, and closed at $55.21, hitting new 52-week high of $55.90.
Tesaro, Inc. (TSRO), declared that Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at the Barclays Global Healthcare Conference at the Loews Hotel in Miami on March 11, 2015 at 2:05 PM Eastern time.
TESARO, Inc. is an oncology-focused biopharmaceutical corporation dedicated to improving the lives of cancer patients.
Kroger Co (NYSE:KR), raised 6.69%, and closed at $74.31, hitting new 52-week high of $74.97.
Formerly on February 27, The Kroger Co. (KR), declared its succession plan for senior vice president of human resources. Kathleen Barclay, 59, Kroger’s senior vice president of human resources, will retire in the fall of 2015.
Timothy Massa, 48, Kroger’s group vice president of human resources and labor relations, will succeed Ms. Barclay in leading these functions, effective upon her retirement.
Katy Barclay to Retire as Senior Vice President, Human Resources:
Ms. Barclay joined Kroger in 2010 in her current position. During her time at Kroger, she has strengthened the HR function to more strongly support and connect the corporation’s family of associates with Kroger’s growing and changing business.
Before joining Kroger in 2010, Katy served as the vice president of global human resources for the General Motors Corp. During her time with GM, she led the automaker’s global human resources organization with a strong focus on building the corporation’s planned HR capability worldwide while focusing on building a strong footprint in emerging and growth markets.
Ms. Barclay is a member of board of directors of American Family Insurance. She serves as chair of the National Academy of Human Resources, and a board member of the Human Resource Policy Association. Ms. Barclay earned a bachelor’s degree in Business at Michigan State University and an MBA at the Massachusetts Institute of Technology. She also serves on the boards of the United Way of Greater Cincinnati and the Cincinnati Symphony Orchestra.
Kroger, one of the world’s largest retailers, employs more than 375,000 associates who serve customers in 2,631 supermarkets and multi-department stores in 34 states and the District of Columbia under two dozen local banner names counting Kroger, City Market, Dillons, Food 4 Less, Fred Meyer, Fry’s, Harris Teeter, Jay C, King Soopers, QFC, Ralphs and Smith’s.
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), enhanced 6.67%, and closed at $1.12.
Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical corporation focused on developing breakthrough treatments for human disease, updated its drug development progress and stated financial results for the three months and year ended December 31, 2014.
In October 2014, Lexicon accomplished a partnership contract with Ipsen Pharma SAS for the commercialization of telotristat etiprate, with a focus on carcinoid syndrome, in markets outside the United States, Canada and Japan. Under the contract, Lexicon is eligible to receive up to about $145 million in aggregate upfront and milestone payments, counting an upfront payment of $23 million. In addition, Lexicon is entitled to receive royalties on net sales of telotristat etiprate by Ipsen.
Also in the fourth quarter of 2014, Lexicon accomplished concurrent debt and equity financings that resulted in gross proceeds of $293.4 million. After fees and offering expenses, the financings resulted in net proceeds of $286.0 million and are reflected in the corporation’s financial results as of December 31, 2014. In the aggregate, the financings comprised of the issuance of about 204.9 million shares of ordinary stock, with gross proceeds of $205.9 million, and $87.5 million in aggregate principal amount of 5.25% convertible senior notes due 2021.
Lexicon is a biopharmaceutical corporation focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon’s research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.
OHR Pharmaceutical Inc (NASDAQ:OHRP) enhanced 6.62%, and closed at $11.43.
Formerly on March 2, Ohr Pharmaceutical, Inc. (OHRP), an ophthalmology research and development corporation, declared the presentation of new data from the INFLUENCE study interim analysis at the 38th Annual Macula Society Meeting which took place February 25-28th, in Scottsdale, Arizona. The new data show an early regression of subretinal hyper-reflective material (SHRM), an anatomic biomarker for the wet form of age-related macular degeneration (wet-AMD), which is consistent with the early gains in visual acuity formerly stated from this study. The data were presented by Jason S. Slakter, MD, Chief Medical Officer at Ohr and Clinical Professor of Ophthalmology, NYU School of Medicine.
The INFLUENCE study is a nine-month Phase II clinical trial evaluating Squalamine Eye Drops (OHR-102) for the treatment of wet-AMD. Formerly declared interim data demonstrated that the combination of OHR-102 plus Lucentis(R) resulted in a meaningful and clinically relevant improvement in visual acuity contrast with Lucentis monotherapy. OHR-102 appeared to have a rapid onset of action, with differences between the combination and control arms observed as early as 4 weeks and ongoing to raise at week 12. At the end of the study, patients treated with the combination of OHR-102 plus Lucentis were still improving. The dramatic and early vision gains observed are believed to result in part from the regression of SHRM, which is widely considered to be a combination of neovascular tissue, pre-fibrotic material and other sub retinal exudative and inflammatory debris.
Ohr Pharmaceutical, Inc. is an ophthalmology research and development corporation whose lead product, Squalamine, is being studied as an eye drop formulation (OHR-102) in several corporation-sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases. These diseases comprise the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy.
